Profluent Bio

Profluent Bio provides an AI-based protein design platform that uses deep generative models to design novel, functional proteins for drug discovery and biotechnology applications. The company approach treats protein design as an authorship problem, using AI to write new biology by creating proteins either inspired by natural scaffolds or designed from scratch. Its landmark achievement is OpenCRISPR, the world first AI-designed gene editor, demonstrating the practical potential of AI-authored biological systems. Profluent partners with major pharmaceutical companies including Eli Lilly to develop AI-designed proteins for therapeutic applications. The platform applies across diverse fields including new therapeutics, industrial enzymes, and agriculture, revolutionizing how complex challenges in protein design are addressed. The company expert team combines machine learning and biology expertise to unlock solutions that would be difficult or impossible through traditional protein engineering methods. Founded in 2022 and headquartered in Berkeley, California, Profluent Bio has raised $150 million in Series B funding from investors including Spark Capital, Insight Partners, Altimeter Capital, Bezos Expeditions, Air Street Capital, AIX Ventures, Phoenix Venture Partners, and Convergent Ventures.